Literature DB >> 32983543

Individuals with a Rh-positive but not Rh-negative blood group are more vulnerable to SARS-CoV-2 infection: demographics and trend study on COVID-19 cases in Sudan.

S A H Taha1, M E M Osman2, E A A Abdoelkarim3, M A I Holie4, M M Elbasheir5, N M K Abuzeid6, S A Al-Thobaiti7, S B Fadul8, E H E Konozy9.   

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In Sudan, several haematological studies were conducted to study the ABO blood group distribution among the population, in which the O blood group was dominant followed by the A blood group. However, there is no systematic study into any correlation between COVID-19 and the population's blood group types, therefore we have intended to study the possible effect of blood group on the acquisition of SARS-CoV-2 infection. A questionnaire-based case-control study was carried out on 557 individuals with COVID-19 in Sudan; factors such as age, blood group, previous malaria infection, history of ailments such as diabetes, hypertension and symptoms suffered were also considered and analysed. More women were infected than men, and individuals between 25 and 35 years were the most affected age group. O Rhesus-positive (O+) blood group was the least affected by the disease while A Rhesus-positive (A+) individuals were the most vulnerable. Fatigue, fever and loss of smell were the major symptoms among the patients, but 13% of SARS-COV-2-positive individuals remained asymptomatic. As the Sudan population is largely constituted of O Rhesus-positive inhabitants (approximately 50%) these results might explain the relatively lower COVID-19 incidence in the country.
© 2020 Published by Elsevier Ltd.

Entities:  

Keywords:  Blood group A; Sudan; blood group O; coronavirus disease 2019; questionnaire; susceptibility

Year:  2020        PMID: 32983543      PMCID: PMC7505818          DOI: 10.1016/j.nmni.2020.100763

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Introduction

Coronavirus disease 2019 (COVID-19) is a highly transmittable disease caused by the recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first detected and identified in December 2019 in Wuhan, China [1]. From there, it spread worldwide and has devastated the economy and growth of many countries in the developed and developing world and has caused a death toll of more than 500 000 [2]. The virus was first named 2019-nCoV by the WHO, but was later renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the coronavirus study group of the International Committee on Taxonomy of Viruses [3]. The rapid spread and rise of the disease in all continents of the world sent an alert to scientists to screen for the characteristics that might make some individuals more susceptible to the virus, as well as risk factors that would increase the severity and progression of the disease. High SARS-CoV-2 infection rate is associated with old age, diabetes, hypertension, chronic respiratory disease and cardiovascular disease [4]. An association of human ABO blood group types with many diseases has been known since the 1950s [5] and was recently reviewed by Liumbruno and Franchini [6]. For example, individuals with non-O blood groups were more prone to develop coronary heart disease and venous thromboembolism compared with individuals with O blood type [7]. Another Malaysian group conducted a study to correlate between ABO blood group types and the probability of developing diabetes mellitus; the study concluded that people with A and O blood groups had the lowest chances of having diabetes [8]. ABO blood groups and susceptibilities to different types of cancers have also been studied. Individuals with B blood groups were found to have the least risk of gastrointestinal, colorectal, stomach and bladder cancer [9]. Several studies have also reported close associations between ABO blood types and susceptibility to malaria. Individuals with blood group A are highly susceptible to Plasmodium falciparum infection, whereas blood group O provides protection against severe malaria; the mechanism of this protection is based on the rosette formation phenomenon [10]. The same noticeable selectivity of the malaria parasite with the ABO blood group system is proved to apply to SARS-CoV-2; individuals with O blood group had the lowest susceptibility to virus infection whereas the A blood type had the highest risk [11,12]. In Sudan, several haematological studies were conducted in different states to find the blood group dissemination pattern among populations, in which the O blood type was the dominant, followed by A, then B, and finally AB with slight differences among these studies [13,14]. So far, there is no systematic study that has been done in Sudan to correlate between COVID-19 and the population's blood group types, so in this study, we have investigated the possible correlation between blood groups and the acquisition of COVID-19. In addition, factors such as previous infection with malaria, sex, age, diseases such as diabetes and hypertension, as well as the number of symptoms suffered, were also studied. To the best of our knowledge, this is the first study in Sudan specifically, and Africa in general, to correlate between the ABO blood system and contracting COVID-19.

Methods

Study design and setting

This case–control study based on an online survey administered through a web browser was conducted on 557 individuals with confirmed COVID-19. Information about gender, age, blood group, COVID-19 symptoms, previous history of infection with malaria and chronic disease were collected through the questionnaire. Data from 1000 healthy volunteers were extracted from the medical registry of Omdurman Maternity Hospital, Omdurman, Sudan.

COVID-19 confirmation

SARS-COV-2 infection was confirmed at medical centres and hospitals certified by the Ministry of Health, using AccuPower® COVID-19 Real-Time RT-PCR Kit (Bioneer Corporation, Daejeon, South Korea) according to the manufacturer's instructions.

Statistical analysis

Data were statistically analysed using SPSS Version-20 (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp, USA). The significance of the results was investigated using one-tailed z-test at significance level p 0.001, and two-tailed binary logistic regression. One-way analysis of variance was used for the analysis of variance.

Ethical consideration

All patients who participated in this questionnaire were informed about the aim and objectives of the study and they agreed to participate. Ethical approval for the individuals who participated as controls was obtained from the ethics committee of Omdurman Maternity Hospital.

Results

Among the 557 participants with COVID-19, 234 (42%) were male and 323 (58%) were female; with female participants more likely to get COVID-19 than male (OR 0.739, 95% CI 0.6–0.911, p 0.005). A large age group range was used from <18 years to 55 years, in which the majority of COVID-19 patients among participants were between 26 and 35 years (41.8%), followed by 36–45 years (22.6%) and finally 19–25 years (21.6%). Seventy patients were reported to be from 46 to 56 years of age (12.6%) and only eight patients (1.4%) were <18 years old. Women with COVID-19 presented a healthier status than male patients with only 4% and 8% suffering from diabetes and hypertension, respectively (Fig. 1).
Fig. 1

Distribution of individuals with COVID-19 according to age and gender.

Distribution of individuals with COVID-19 according to age and gender. Distribution of blood group types among the patients is shown in Table 1; 241 (43%) of the total study population were of O blood group (O Rhesus positive (+ve) 39%, O Rhesus-negative (–ve) 4.5%); 180 patients (32%) were of A blood group (A +ve 30.9%, A –ve 1.4%); 102 patients (18.3%) had B blood group (B +ve 16.5%, B –ve 1.8%), and finally 34 (6.1%) had AB blood group (AB +ve 5.6%, AB –ve 0.5%). The susceptibility to SARS-CoV-2 infection was correlated to A +ve blood group (OR 1.316, 95% CI 0.782–2.215, p 0.008).
Table 1

z-test and logistic regression statistical analysis for blood group susceptibility towards infection with COVID-19

COVID-19
Control
z valuep0.001p0.05OR95% CI
n (%)n (%)
A +ve172 (30.9)251 (25.1)0.00080.0081.3160.782–2.215
A –ve8 (1.4)21 (2.1)0.120.5170.7310.284–1.886
B +ve92 (16.5)173 (17.3)0.330.9401.0210.592–1.762
B –ve10 (1.8)18 (1.8)0.50.8901.0670.429–2.655
AB +ve31 (5.6)32 (3.8)0.00060.0781.8600.932–3.712
AB –ve3 (0.5)2 (0.2)0.060.2632.8800.451–18.378
O +ve216 (38.8)455 (45.5)0.00060.7220.9110.547–1.518
O –ve
25 (4.5)
48 (4.8)
0.37
a


Total5571000

This parameter is set to zero because it is redundant.

z-test and logistic regression statistical analysis for blood group susceptibility towards infection with COVID-19 This parameter is set to zero because it is redundant. A total of 406 patients (72.9%) did not have any chronic disease, while 52 (9.7%) had diabetes and hypertension; 446 patients (80.1%) had experienced a previous malaria infection, of whom 20% had been infected within the previous 3 years. The other individuals with COVID-19 had no previous history of malaria infection (Fig. 2).
Fig. 2

Individuals with COVID-19 and their back history of malaria infection.

Individuals with COVID-19 and their back history of malaria infection. Of the individuals with COVID-19, 87% presented with different combinations of symptoms. The major symptoms experienced by patients were as follows: fatigue (64%), headache (54.4%), fever (51%), anosmia (47.8%), sore throat (42.5%), ageusia (38.1%), anorexia (37.3%), cough (36.4%), diarrhoea (32.9%) and finally shortness of breath (25.7%). Seventy-three (13%) of those who were clinically confirmed SARS-COV-2-positive remained asymptomatic throughout their isolation period (Fig. 3). Of these asymptomatic patients, 18.2% had O +ve blood whereas 14.6% had A +ve blood. However, there was no significant difference in blood distribution between symptomatic and asymptomatic COVID-19 patients (OR 0.880, 95% CI 0.512–1.511, χ2 0.05 0.827). The one-way analysis of variance showed no variation between the ages and blood groups (α = 0.05). The relations between the blood groups and demography, major COVID-19 symptoms and common chronic diseases (diabetes and hypertension) are shown in Fig. 4.
Fig. 3

Percentage of major symptoms suffered by individuals with COVID-19.

Fig. 4

Blood group relationship of individuals with COVID-19 with (a) gender, (b) age group, (c) major symptoms and (d) chronic diseases.

Percentage of major symptoms suffered by individuals with COVID-19. Blood group relationship of individuals with COVID-19 with (a) gender, (b) age group, (c) major symptoms and (d) chronic diseases.

Discussion

To assess the current pandemic trend of SARS-CoV-2 infection in Sudan, the current study was planned and executed in the period from May to August 2020. In total, 565 questionnaires were filled online and submitted, of which eight were improperly filled and therefore excluded from the study.

Demographic studies

The gender ratio in the Sudan population is almost 1:1 males to females; however, based on the current study the susceptibility to SARS-CoV-2 infection appears to be more towards females than males (1.4:1). In 125 countries, areas and territories surveyed, UNWOMEN reported that men (54%) were more vulnerable to COVID-19 infection than women (46%) [15]. The current study's results also contradict a study performed in India, in which incidence of male patients (76%) was significantly higher than that of females (24%) [16], whereas in China, the prevalence between genders was equal, but the mortality rate was higher in men than women [17,18]. As this study was meant to explore the prevalence, no data about the mortality rate among genders were collected. Analysis of the demographic data of the 557 COVID-19 patients reported in this article revealed that around 86% of patients were between the ages of 19 and 45 years, which indicates that most of those who became infected with SARS-CoV-2 were of working age. Of the 557 patients who filled the questionnaire, only 22 (4%) were older than 56 years. These results are similar to those from India [16]. Another study conducted in Italy revealed that older age groups are more susceptible to SARS-COV-2 infection [19]. As the only available continuous variable within the data set is age, we performed one-way analysis of variance test to correlate between age and blood group, which produced an insignificant correlation between these two factors (mean sample age 32.7 years, α = 0.05). It should be noted that this study was conducted online, but older individuals in a country like Sudan are least exposed to smartphone technologies, so these results might not truly reflect a correct estimate for older individuals who contracted the disease.

Correlation between COVID-19, malaria and ABO blood system

The region falls within the zones where malaria is endemic; it is known that these zones have lower COVID-19 incidence compared with countries that fall outside this zone [[20], [21], [22]]. Zones of malaria endemicity remain a matter of scientific debate in justification of this limited spread [20]. In Sudan, the first case of SARS-CoV-2 infection was reported in mid-February 2020, although the population does not follow the strict social distancing instructed by medical regulations [23], only around 12 500 cases of COVID-19 were officially recorded after 6 months of the onset of the disease in Sudan. Reports that correlate the low incidences of COVID-19 in this zone with malaria infections are accumulating. Some hypotheses have already been put forward to explain the reduced rate of COVID-19 rates in the zones of malaria endemicity. Weather, environmental factors and previous exposure to malaria drugs like hydroxychloroquine were discussed [20,21,24]. This relation was further supported by several characteristics in common between the two diseases. First, both malaria and COVID-19 are observed to be interlinked with the ABO blood group system, in which individuals with the O blood group are protected against severe progression of the diseases, whereas individuals with blood group A are highly susceptible to infections. Second, anti-malarial drugs like chloroquine, hydroxychloroquine, mefloquine and recently artemisinin have been potential choices for COVID-19 treatment [25]. Third, the finding that besides its use of the angiotensin-converting enzyme 2 receptor, SARS-CoV-2 could also invade cells through interaction of the spike protein with the CD147 receptor, a receptor that is used by P. falciparum to cause malaria. Moreover, the nano-lipid Metadichol which inhibits SARS-CoV-2 could equally suppress the P. falciparum from entering erythrocytes [26,27]. The interaction between the virus glycoprotein (spike) and the host receptor is mediated by the virus's spike protein segment S1A of the domain S1, which is a sialic acid-binding lectin that recognizes the sialic acid receptor on the host cell surface [28]. Silva-Filho et al. have hypothesized that the sialic acid-containing host receptors angiotensin-converting enzyme-2 and CD147 are targets for the spike agglutinin [29]. Another hypothesis alleged some possible shared epitope conservation between SARS-CoV-2 and P. falciparum that would trigger related immune responses (personal communication). In our study, though the correlation between contracting COVID-19 and previous malaria infections gave a statistically insignificant relation. However, as we primarily dealt with recovered COVID-19 patients, a similar study on the malaria infection back history of those who died from COVID-19 would have been of more relevance for such a correlation. The fatality of malaria is attributed in part to the invasion of the Plasmodium to the erythrocytes, a process mediated by the P. falciparum reticulocyte-binding protein homologue 5 RH5-basigin/CD147 interactions. Interesting recent findings indicated infection of the host cell by SARS-CoV-2 through spike protein-basigin/CD147 interaction [30]. Blood groups have routinely been related to many ailments such as coronary heart disease, cancer and diabetes [8,31]. A few articles have already been published testing for a relation between COVID-19 and the ABO blood group system [32,33]. Studies have observed the susceptibility of A blood group individuals to SARS-CoV-2 infection, whereas individuals with O blood group are protected against severe progression of the disease. The current study did not deviate from this concept, however, interestingly our study indicates that individuals with A +ve blood group—but not those who are A –ve—are more prone to contract the disease compared with controls (p 0.0008), the same applies to AB +ve individuals, but not AB –ve individuals. On the other hand, O +ve, but not O –ve, are shown to have a statistically significantly reduced number of infections compared with control individuals (p 0.0006). No blood group effect was noticed for B blood group individuals. Testing the possible relation with blood type in the asymptomatic patients gave insignificant results (not shown), which indicates that the susceptibility to SARS-CoV-2 infection is only associated with the blood group rather than the symptoms [12].

Conclusion

This study provided for the first time the demographic features and trends of SARS-CoV-2 infection and symptoms among patients in Sudan. The study also furnished clear data on the association of the ABO blood system among the population with COVID-19. Furthermore, the study corroborated that individuals with A +ve, but not A –ve are more vulnerable to contracting the disease, whereas O +ve rather than O –ve individuals are least exposed to severe symptoms of the pandemic. Though some of the data presented in this article replicate the Chinese findings, it remains unique with respect to the Rhesus factor, the variability of symptoms and the gender infection profile. Moreover, the Sudanese population is dominated by the O +ve blood group, which might justify the low COVID-19 spreading rate in the country found in this study. Individuals with blood group A should observe maximum precaution to protect themselves against acquiring SARS-CoV-2 infection, but this study's results should not be considered by O blood carriers as a guarantee that would shield them from the disease, they must still be cautious to avoid increasing risk of infection.
  25 in total

Review 1.  Beyond immunohaematology: the role of the ABO blood group in human diseases.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 2.  Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature.

Authors:  Francesco Dentali; Anna Paola Sironi; Walter Ageno; Sara Turato; Carlo Bonfanti; Francesco Frattini; Silvia Crestani; Massimo Franchini
Journal:  Semin Thromb Hemost       Date:  2012-06-27       Impact factor: 4.180

3.  Incidence of coronavirus disease (COVID-19) and countries affected by malarial infections.

Authors:  Anwar E Ahmed
Journal:  Travel Med Infect Dis       Date:  2020-04-22       Impact factor: 6.211

4.  Blood type, ABO genetic variants, and ovarian cancer survival.

Authors:  Gabriella D Cozzi; Rebecca T Levinson; Hilary Toole; Malcolm-Robert Snyder; Angie Deng; Marta A Crispens; Dineo Khabele; Alicia Beeghly-Fadiel
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

5.  Editorial: COVID-19 Spiraling of Frailty in Older Italian Patients.

Authors:  A M Abbatecola; R Antonelli-Incalzi
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

6.  Structural basis for human coronavirus attachment to sialic acid receptors.

Authors:  M Alejandra Tortorici; Alexandra C Walls; Yifei Lang; Chunyan Wang; Zeshi Li; Danielle Koerhuis; Geert-Jan Boons; Berend-Jan Bosch; Félix A Rey; Raoul J de Groot; David Veesler
Journal:  Nat Struct Mol Biol       Date:  2019-06-03       Impact factor: 15.369

7.  Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan.

Authors:  Qian Fan; Wei Zhang; Bo Li; De-Jia Li; Jian Zhang; Fang Zhao
Journal:  Front Cell Infect Microbiol       Date:  2020-07-21       Impact factor: 5.293

8.  Association between ABO blood groups and risk of SARS-CoV-2 pneumonia.

Authors:  Juyi Li; Xiufang Wang; Jian Chen; Yi Cai; Aiping Deng; Ming Yang
Journal:  Br J Haematol       Date:  2020-05-26       Impact factor: 6.998

9.  Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.

Authors:  Mathieu Gendrot; Isabelle Duflot; Manon Boxberger; Océane Delandre; Priscilla Jardot; Marion Le Bideau; Julien Andreani; Isabelle Fonta; Joel Mosnier; Clara Rolland; Sébastien Hutter; Bernard La Scola; Bruno Pradines
Journal:  Int J Infect Dis       Date:  2020-08-14       Impact factor: 3.623

View more
  7 in total

Review 1.  Emerging Viral Infections, Hypertension, and Cardiovascular Disease in Sub-Saharan Africa: A Narrative Review.

Authors:  Lily D Yan; Sarah S Matuja; Kevin J Pain; Margaret L McNairy; Anthony O Etyang; Robert N Peck
Journal:  Hypertension       Date:  2022-03-11       Impact factor: 9.897

2.  The Impact of ABO Blood Grouping on COVID-19 Vulnerability and Seriousness: A Retrospective Cross-Sectional Controlled Study among the Arab Community.

Authors:  Nagla A El-Shitany; Manal El-Hamamsy; Ahlam A Alahmadi; Basma G Eid; Thikryat Neamatallah; Haifa S Almukadi; Rana A Arab; Khadija A Faddladdeen; Khayria A Al-Sulami; Safia M Bahshwan; Soad S Ali; Steve Harakeh; Shaimaa M Badr-Eldin
Journal:  Int J Environ Res Public Health       Date:  2021-01-01       Impact factor: 3.390

Review 3.  The relationship between blood groups and risk of infection with SARS-CoV-2 or development of severe outcomes: A review.

Authors:  Pourya Shokri; Saeid Golmohammadi; Maryam Noori; Seyed Aria Nejadghaderi; Kristin Carson-Chahhoud; Saeid Safiri
Journal:  Rev Med Virol       Date:  2021-05-14       Impact factor: 11.043

4.  ABO and Rhesus Blood Groups in Acute Puumala Hantavirus Infection.

Authors:  Johanna Tietäväinen; Outi Laine; Satu Mäkelä; Heini Huhtala; Ilkka Pörsti; Antti Vaheri; Jukka Mustonen
Journal:  Viruses       Date:  2021-11-13       Impact factor: 5.048

5.  Role of ABO Blood Group in SARS-CoV-2 Infection in Households.

Authors:  Ales Janda; Corinna Engel; Jonathan Remppis; Sigrid Enkel; Andreas Peter; Sebastian Hörber; Tina Ganzenmueller; Sarah Schober; Christof Weinstock; Eva-Maria Jacobsen; Dorit Fabricius; Maria Zernickel; Thomas Stamminger; Andrea Dietz; Hans-Jürgen Groß; Sebastian F N Bode; Anneke D M Haddad; Roland Elling; Maximilian Stich; Burkhard Tönshoff; Philipp Henneke; Klaus-Michael Debatin; Axel R Franz; Hanna Renk
Journal:  Front Microbiol       Date:  2022-05-06       Impact factor: 5.640

6.  Systematic review and meta-analysis of the effect of ABO blood group on the risk of SARS-CoV-2 infection.

Authors:  George Balaouras; Paolo Eusebi; Polychronis Kostoulas
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

Review 7.  Association between ABO blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: a literature review of 23 studies.

Authors:  Yujia Zhang; Rachael Garner; Sana Salehi; Marianna La Rocca; Dominique Duncan
Journal:  Ann Hematol       Date:  2021-03-08       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.